Media headlines about CombiMatrix (NASDAQ:CBMX) have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CombiMatrix earned a news sentiment score of -0.02 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.4840191204244 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
CombiMatrix (CBMX) traded down $0.20 during mid-day trading on Monday, reaching $6.25. The company’s stock had a trading volume of 51,800 shares, compared to its average volume of 119,111. The company has a quick ratio of 3.03, a current ratio of 3.23 and a debt-to-equity ratio of 0.02. The company has a market cap of $18.40, a PE ratio of -8.45 and a beta of 0.85. CombiMatrix has a 1 year low of $2.20 and a 1 year high of $8.20.
CombiMatrix (NASDAQ:CBMX) last posted its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $4.01 million for the quarter, compared to analysts’ expectations of $4.19 million. CombiMatrix had a negative return on equity of 27.90% and a negative net margin of 13.19%. During the same quarter last year, the business earned ($0.38) EPS. equities research analysts expect that CombiMatrix will post -0.59 earnings per share for the current fiscal year.
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.
Receive News & Ratings for CombiMatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix and related companies with MarketBeat.com's FREE daily email newsletter.